KR950703336A - Treatment of cachexia and inhibition of IL-6 activity - Google Patents

Treatment of cachexia and inhibition of IL-6 activity Download PDF

Info

Publication number
KR950703336A
KR950703336A KR1019950701386A KR19950701386A KR950703336A KR 950703336 A KR950703336 A KR 950703336A KR 1019950701386 A KR1019950701386 A KR 1019950701386A KR 19950701386 A KR19950701386 A KR 19950701386A KR 950703336 A KR950703336 A KR 950703336A
Authority
KR
South Korea
Prior art keywords
cachexia
result
infection
sulfate
containing compound
Prior art date
Application number
KR1019950701386A
Other languages
Korean (ko)
Inventor
기드온 스트라스만
Original Assignee
가츠히로 도미타
오츠카 어메리카 파마슈티컬, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가츠히로 도미타, 오츠카 어메리카 파마슈티컬, 인코포레이티드 filed Critical 가츠히로 도미타
Publication of KR950703336A publication Critical patent/KR950703336A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)

Abstract

본 발명은 환자 악액질(cachexia)을 치료하고 IL-6생활성을 저해하는 방법에 관한 것이다.The present invention relates to methods of treating patient cachexia and inhibiting IL-6 bioactivity.

이 방법은 효과적인 양의 설페이트-함유 화합물, 예를들면, 수라민, 수라민의 유도체, 펜토산 폴리설페이트(Pentosan Polysulfate ), 덱스트란 설페이드(Dextran sulfate)를 환자에게 투여함으로써 성취된다.This method is accomplished by administering to the patient an effective amount of sulfate-containing compound, such as suramin, a derivative of suramin, Pentosan Polysulfate, Dextran sulfate.

본 발명은 또한 IL-6와 관련된 질병들과도 대항하는데 효과적이다.The invention is also effective in combating diseases associated with IL-6.

Description

악액질의 치료와 IL-6 활성의 저해Treatment of cachexia and inhibition of IL-6 activity

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 수라민의 사용으로 인한 C-26 악액질의 시간에 따른 저해를 설명하는 그래프이다.FIG. 1 is a graph illustrating the time-dependent inhibition of C-26 cachexia due to the use of suramin.

제2도는 생체내에서 종양(C-26)성장에 대한 수라민 결핍효과를 설명하는 그래프이다.2 is a graph illustrating the effect of suramin deficiency on tumor (C-26) growth in vivo.

제3도는 수라민의 사용으로 인한 C-26 악앨질의 복용량 의존성 저해를 설명하는 그래이프이다.FIG. 3 is a graph illustrating dose-dependent inhibition of C-26 axalyl due to the use of suramin.

제4도는 수라민의 사용으로 인한 투르펜틴-유도(turpentine-induced)수척의 방지를 설명하는 그래프이다.4 is a graph illustrating the prevention of turpentine-induced repelling due to the use of suramin.

제5도는 수라민의 사용으로 인한 IL-6의 생활성을 저해를 설명하는 그래프이다.5 is a graph illustrating the inhibition of bioactivity of IL-6 due to the use of suramin.

Claims (20)

악액질 치료에 효과적인 양의 펜토산 폴리설페이트 혹은 덱스트란 설페이트를 환자에게 투여하는 단계를 포함하는 악액질 치료 방법.A method for treating cachexia comprising administering to a patient an amount of pentosan polysulfate or dextran sulfate effective to treat cachexia. 제1항에 있어서, 상기 악액질은 하나 또는 2이상의 미생물에 의한 감염의 결과인 방법.The method of claim 1, wherein the cachexia is a result of infection by one or more microorganisms. 제2항에 있어서, 상기 악액질은 박테리아에 의한 감염의 결과인 방법.The method of claim 2, wherein the cachexia is a result of infection by bacteria. 제3항에 있어서, 상기 악액질은 그람-음성 박테리아에 의한 감염의 결과인 방법.The method of claim 3, wherein the cachexia is a result of infection by Gram-negative bacteria. 제3항에 있어서, 상기 악액질은 그람-음성 박테리아에 의한 감염의 결과인 방법.The method of claim 3, wherein the cachexia is a result of infection by Gram-negative bacteria. 제2항에 있어서, 상기 악액질은 원생동물에 의한 감염의 결과인 방법.The method of claim 2, wherein the cachexia is a result of infection by a protozoa. 제2항에 있어서, 상기 악액질은 곰팡이에 의한 감염의 결과인 방법.The method of claim 2, wherein the cachexia is a result of infection by a fungus. 제2항에 있어서, 상기 악액질은 곰팡이에 의한 감염의 결과인 방법.The method of claim 2, wherein the cachexia is a result of infection by a fungus. 제1항에 있어서, 상기 악액질은 기생충에 의한 감염의 결과인 방법.The method of claim 1, wherein the cachexia is a result of infection by a parasite. 제2항에 있어서, 상기 악액질은 하나 또는 2이상의 형태를 가진 암의 결과인 방법.The method of claim 2, wherein the cachexia is a result of cancer in one or more forms. 제1항에 있어서, 상기 복용양은 주당 약0.01g 내지 10g의 양인 방법.The method of claim 1, wherein the dosage amount is about 0.01 g to 10 g per week. 제11항에 있어서, 상기의 복용양은 분할된 양으로 투여하는 것인 방법.The method of claim 11, wherein said dosage is administered in divided amounts. IL-6 생활성을 억제하기에 효과적인 양의 설페이트-함유 화합물을 환자에게 복용시키는 단계를 포함하는 IL-6 생활성의 저해방법.A method of inhibiting IL-6 bioactivity, comprising administering to a patient an amount of a sulfate-containing compound effective to inhibit IL-6 bioactivity. 제13항에 있어서, 상기 설페이트-함유 화합물은 수라민, 수라민유도체, 펜토산 폴리설페이트 및 덱스트란 설페이트로 이루어진 군으로부터 선택된 방법.The method of claim 13, wherein the sulfate-containing compound is selected from the group consisting of suramin, suramin derivatives, pentosan polysulfate, and dextran sulfate. 제13항에 있어서, 투여량은 주당 약 0.01 내지 10g인 방법.The method of claim 13, wherein the dosage is about 0.01-10 g per week. 제15항에 있어서, 상기 투여량을 분할된 양으로 투여하는 방법.The method of claim 15, wherein said dosage is administered in divided amounts. 체중손실을 경감하거나 제거하는데 효과적인 양의 설페이트-함유 화합물을 환자에게 투여하는 단계를 포함하는, 신체지방과 근육의 수척에 의한 체중손실을 경감 또는 제거하는 방법.A method of alleviating or eliminating weight loss due to retraction of body fat and muscle, comprising administering to the patient an amount of sulfate-containing compound effective to alleviate or eliminate weight loss. 제17항에 있어서, 상기 설페이트-함유 화합물은 수라민, 수라민유도체, 펜토산폴리설페이트 및 덱스트란 설페이트로 이루어진 군으로부터 선택된 방법.The method of claim 17, wherein the sulfate-containing compound is selected from the group consisting of suramin, suramin derivatives, pentosan polysulfate, and dextran sulfate. IL-6 관련 질병치료에 효과적인 양의 설페이트,-함유 화합물을 환자에게 복용시키는 단계를 포함한 IL-6관련 질병의 치료방법.A method of treating IL-6 related diseases, comprising administering to a patient an amount of sulfate, -containing compound effective to treat an IL-6 related disease. 제19항에 있어서, 상기 IL-6 관련된 질병은 악액질, 폴리크로날 B-세포이상, 자동면역병, 심장 점맥증, 류마치스관절염, 캐슬맨 병(Castleman′s),AIDS, 알코올성 간경화증, 증식성 병, 메산지얼 증식성 글로메룰로네프리티스(mesangial proliferative glomerulonephritis), 마른 버짐, 마리그나시(malignancy), 플라즈마시토마(plasmacytoma), 미에로마, 림포마, 뤼케미아, 및 신장세포 칼시노마인 방법.20. The disease according to claim 19, wherein the IL-6 related disease is cachexia, polyclonal B-cell aberration, autoimmune disease, cardiac oculopathy, rheumatoid arthritis, Castleman's, AIDS, alcoholic cirrhosis, proliferative Disease, mesogenic proliferative glomerulonephritis, dry ringworm, malignancy, plasmacyytoma, myelo, lymphoma, luchemia, and renal cell calcinemaine Way. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950701386A 1992-10-13 1993-10-12 Treatment of cachexia and inhibition of IL-6 activity KR950703336A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95937192A 1992-10-13 1992-10-13
US07/959371 1992-10-13
US13401993A 1993-10-08 1993-10-08
US03/134019 1993-10-08
PCT/US1993/009527 WO1994008574A1 (en) 1992-10-13 1993-10-12 Treatment of cachexia and inhibition of il-6 activity

Publications (1)

Publication Number Publication Date
KR950703336A true KR950703336A (en) 1995-09-20

Family

ID=26831899

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950701386A KR950703336A (en) 1992-10-13 1993-10-12 Treatment of cachexia and inhibition of IL-6 activity

Country Status (5)

Country Link
EP (1) EP0664700A1 (en)
JP (1) JPH08502295A (en)
KR (1) KR950703336A (en)
CA (1) CA2146988A1 (en)
WO (1) WO1994008574A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0811384B1 (en) * 1995-02-13 2006-06-21 Chugai Seiyaku Kabushiki Kaisha Muscle protein decomposition inhibitor containing il-6 receptor antibody
FR2808687B1 (en) * 2000-04-27 2003-12-05 Goemar Lab Sa MEDICAMENT CONTAINING POLYSACCHARIDE SUBSTANCES FOR THE ACTIVATION OF APOPTOSIS
EP1557170A3 (en) * 2000-06-30 2005-09-21 Polydex Pharmaceuticals Limited Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections
EP1296691B1 (en) * 2000-06-30 2005-11-02 Polydex Pharmaceuticals Limited Use of cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infections
DK1334731T3 (en) 2000-10-25 2008-05-26 Chugai Pharmaceutical Co Ltd Preventive or therapeutic agent for psoriasis comprising anti-IL-6 receptor antibody as active ingredient
US20030181416A1 (en) * 2002-01-10 2003-09-25 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
WO2010016628A1 (en) * 2008-08-04 2010-02-11 Sammy Opiyo Conjugated suramin amino compounds for medical conditions
WO2011109469A1 (en) * 2010-03-03 2011-09-09 Neocutis Sa Compositions and methods for treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
WO2022114111A1 (en) * 2020-11-27 2022-06-02 マルホ株式会社 Pharmaceutical or cosmetic composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9024738D0 (en) * 1990-11-14 1991-01-02 Erba Carlo Spa A new method of treatment of tumor necroisis factor(tnf)-related diseases

Also Published As

Publication number Publication date
WO1994008574A1 (en) 1994-04-28
CA2146988A1 (en) 1994-04-28
EP0664700A1 (en) 1995-08-02
JPH08502295A (en) 1996-03-12

Similar Documents

Publication Publication Date Title
KR920700200A (en) 19-nor-vitamin D compound
HK1035677A1 (en) Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity.
CA2263203A1 (en) 3,6-ketal and enol ether macrolide antibiotics
KR940018089A (en) Prevention and treatment for radiation damage of internal tissue
KR950703336A (en) Treatment of cachexia and inhibition of IL-6 activity
RU2004135078A (en) HERBAL MOLECULE AS A POTENTIAL ANTI-VEHICLE MEDICINE
ATE229809T1 (en) USE OF COMPOUNDS CONTAINING MAGNESIUM FOR THE TREATMENT OR PROPHYLAXIS OF CANCER AND AUTOIMMUNE DISEASES
MX2021001985A (en) Platelet count-agnostic methods of treating myelofibrosis.
WO1991002529A2 (en) Product and method for killing abnormal vertebrate cells
Southwick et al. Chemotherapy of experimental streptococcal endocarditis: Part III Failure of a bacteriostatic agent (tetracycline) in prophylaxis
RU94045271A (en) Use of 2-phenyl-3-aroylbenzothiophenes for terner's syndrome inhibition
CN110664807B (en) Pharmaceutical composition with synergistic anti-melanoma efficacy and application thereof
FR2393579A1 (en) ANTIVIRAL AGENT AND ITS APPLICATION TO THE TREATMENT OF VIRAL DISORDERS
JPS6230715A (en) Antirumoral preparation
DE3786456T2 (en) COMBINATIONS OF NECROSIS TUMOR FACTORS AND ANTI-INFLAMMATORY AGENTS FOR THE TREATMENT OF Vicious AND NON-Vicious DISEASES.
JPS57126420A (en) Drug for digestive organ
Powell et al. Metronidazole combined with diloxanide furoate in amoebic liver abscess
KR890701112A (en) Method for treating and treating hepatitis virus infectious disease using 1- (2'-deoxy-2'-fluoro-beta-D-arabino-furanosyl) -5-ethyluracil
RU98101105A (en) NEW APPLICATION FOR MEDICAL PURPOSES
US4654333A (en) Treatment of multiple sclerosis
Ray et al. Comparative efficacy of GO 10213 and some nitroimidazoles against Trichomonas vaginalis and T. foetus in mice infected subcutaneously
US3551566A (en) Fish disease treating composition and method of using same
DE3275060D1 (en) Use of beta-(1-adamantyl)-alpha, alpha-dimethylethylamine for the manufacture of a medicament for the treatment of otitis externa in dogs
EP0316163B1 (en) Tetronasin or derivatives thereof for veterinary treatment
Irie et al. Influence of the radiation protective agents on the therapeutical effects of radiations for malignant tissues

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid